Abstract | OBJECTIVE: DESIGN: INTERVENTIONS: Male CD mice (20-22 g) were allocated into four groups (n=10 for each group): (a) Cerulein+vehicle group. Mice were treated hourly (x 5) with cerulein (50 microg/kg, in saline solution, i.p.); (b) Rosiglitazone group (same as the Cerulein+vehicle group but were administered rosiglitazone, 10 mg/kg bolus, 30 min prior to cerulein); (c) Sham+saline group. Mice were treated with saline instead of cerulein; (d) Sham+Rosiglitazone. Identical to Rosiglitazone group except that the saline was administered instead of cerulein. Mice were killed at 6 h after the induction of pancreatitis. Blood samples, pancreas, and lungs were collected. MEASUREMENTS AND RESULTS: Infiltration of pancreatic and lung tissue with neutrophils was associated with enhanced lipid peroxidation. Immunohistochemical examination demonstrated a marked increase in immunoreactivity for nitrotyrosine and for ICAM-1 in the pancreas of cerulein-treated mice. In contrast, the degree of (a) pancreatic inflammation and tissue injury, (b) upregulation/formation of ICAM-1 and nitrotyrosine, and (c) neutrophils infiltration was markedly reduced in pancreatic tissue obtained from rosiglitazone-treated mice. CONCLUSION:
|
Authors | Salvatore Cuzzocrea, Barbara Pisano, Laura Dugo, Angela Ianaro, Domenico Britti, Nimesh S A Patel, Rosanna Di Paola, Tiziana Genovese, Massimo Di Rosa, Achille P Caputi, Christoph Thiemermann |
Journal | Intensive care medicine
(Intensive Care Med)
Vol. 30
Issue 5
Pg. 951-6
(May 2004)
ISSN: 0342-4642 [Print] United States |
PMID | 14985957
(Publication Type: Journal Article)
|
Chemical References |
- Cell Adhesion Molecules
- Receptors, Cytoplasmic and Nuclear
- Thiazolidinediones
- Transcription Factors
- Rosiglitazone
- Ceruletide
- Lipase
- Amylases
|
Topics |
- Acute Disease
- Amylases
(blood)
- Animals
- Cell Adhesion Molecules
(metabolism)
- Ceruletide
(toxicity)
- Lipase
(blood)
- Lipid Peroxidation
- Male
- Mice
- Pancreatitis
(drug therapy, enzymology, metabolism)
- Receptors, Cytoplasmic and Nuclear
(agonists)
- Rosiglitazone
- Thiazolidinediones
(therapeutic use)
- Transcription Factors
(agonists)
|